The Regulatory Divergence: Why Countries Are Moving in Opposite Directions

The global nicotine regulatory landscape is diverging, not converging. The United Kingdom has embraced vaping as a harm-reduction tool, with the NHS actively promoting it as a cessation aid. Australia has effectively banned recreational vaping, requiring a prescription for nicotine e-liquid. The United States is fragmented: the FDA has authorized some vaping products through the PMTA process while state-level flavor bans and shipping restrictions have severely restricted the market. New Zealand, Canada, Sweden, and Japan have each charted their own paths. The divergence is not random. It reflects different weightings of the same evidence, different institutional histories with the tobacco industry, and different cultural attitudes toward nicotine and addiction. Understanding why countries are moving in opposite directions is essential for understanding where global nicotine policy is heading.

The UK's embrace of harm reduction is rooted in the institutional culture of British public health. The UK has a strong tradition of evidence-based medicine, a National Health Service that integrates prevention and treatment, and a public health establishment (Public Health England, now the Office for Health Improvement and Disparities) that's relatively independent of political pressure. The UK's annual evidence reviews on e-cigarettes, which consistently support the 'at least 95% less harmful' estimate, have provided the evidentiary foundation for progressive policy. And the UK's experience—accelerated smoking declines without a youth vaping epidemic comparable to the U.S.—has validated the approach. The UK model is the strongest counterexample to the claim that harm-reduction policies inevitably lead to youth nicotine epidemics.

Australia's rejection of harm reduction is rooted in a different institutional history. Australian tobacco control has been dominated by a precautionary, abstinence-oriented approach, with a strong emphasis on the tobacco industry as an irreconcilable adversary. The prescription-only model for vaping reflects both the institutional commitment to precaution and the political influence of a public health establishment that's deeply skeptical of the tobacco industry and of any product associated with it. Australia's approach has been effective for reducing smoking—Australian smoking rates are among the lowest in the world—but it has also restricted access to reduced-risk products for smokers who can't or won't quit with approved methods. The Australian model is the strongest counterexample to the claim that restrictive policies are incompatible with smoking reduction.

The United States' fragmentation reflects the complexity of American governance. Federal regulation (the FDA, the PMTA process) coexists with state-level policies (flavor bans, taxes, retail restrictions) and local ordinances. The result is a patchwork where the nicotine landscape varies dramatically by jurisdiction. The fragmentation is partly a function of federalism—different states making different policy choices—and partly a function of the political polarization that has made nicotine policy a culture-war issue in ways it isn't in the UK or Australia. The U.S. experience demonstrates that the same evidence can produce different policies in different political contexts within a single country.

The divergence is producing a global natural experiment. The countries that have embraced harm reduction (UK, Sweden, New Zealand) will generate epidemiological evidence on the long-term effects of widespread non-combustible nicotine use. The countries that have rejected it (Australia) will generate evidence on the effects of restrictive policies. The comparison between these trajectories will, over the coming decades, provide the evidence that the current debate lacks. The natural experiment is not controlled—the countries differ in many ways beyond their nicotine policies—but it's the best evidence we're going to get. The global regulatory divergence is both a challenge for international coordination and an opportunity for learning.

The question for the future is whether the divergence will persist or whether the accumulating evidence will produce convergence. The UK's evidence—accelerated smoking declines without a youth epidemic—will either continue to accumulate, strengthening the case for harm reduction, or be complicated by emerging data on long-term vaping effects. Australia's evidence—continued smoking declines under restrictive policies—will either demonstrate that prohibition can work, or show that smokers denied access to reduced-risk products continue to smoke at rates that would have been lower with harm reduction. The natural experiment is running. The results will arrive over the next decade. The direction of global nicotine policy—toward convergence around harm reduction, or continued divergence—will be determined by what those results show.